Arie Belldegrun raises $300M, grabs Pfizer’s allogeneic CAR-T portfolio and launches a groundbreaking drive to commercialization admin April 4, 2018 PR You Might Also Like The biomed market is flourishing, so how can the generics companies stay out of the party? May 29, 2019 ‘Greatest emerging market’? Cannabis-based drug R&D finally going mainstream May 27, 2019 9 devices that could revolutionize current treatments May 13, 2019
The biomed market is flourishing, so how can the generics companies stay out of the party? May 29, 2019
